Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Trial Of Pembrolizumab And Nintedanib (PEMBIB)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02856425
Recruitment Status : Suspended (Safety event)
First Posted : August 4, 2016
Last Update Posted : January 3, 2019
Sponsor:
Information provided by (Responsible Party):
Gustave Roussy, Cancer Campus, Grand Paris

Brief Summary:
Both anti-angiogenesis and anti PD1 immunotherapy have shown beneficial efficacy in solid tumors and in particular in NSCLC. Therefore it is of interest to investigate whether the combination of these two approaches is tolerable. Moreover, comprehensive pre-clinical and clinical rationale sustain the hypothesis that anti-VEGF could synergize with immunotherapy for the benefit of the patients.

Condition or disease Intervention/treatment Phase
Patients With Any Advanced Solid Tumors Drug: Nintedanib Drug: Pembrolizumab Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 18 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase Ib Trial Of Pembrolizumab And Nintedanib
Actual Study Start Date : November 10, 2016
Estimated Primary Completion Date : July 2021
Estimated Study Completion Date : July 2026

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: NSCLC of adenocarcinoma tumor hist Drug: Nintedanib
Nintedanib oral tablets. An angiokinase inhibitor targeting VEGFR 1-3, FGFR 1-3, and PDGFR α/β as well as RET. Refer to current IB for product details

Drug: Pembrolizumab
Pembrolizumab, Intravenous. An IgG4 anti-PD-1 blocking monoclonal antibody. Refer to current IB for product details

Experimental: NSCLC of squamous cell tumor histo Drug: Nintedanib
Nintedanib oral tablets. An angiokinase inhibitor targeting VEGFR 1-3, FGFR 1-3, and PDGFR α/β as well as RET. Refer to current IB for product details

Drug: Pembrolizumab
Pembrolizumab, Intravenous. An IgG4 anti-PD-1 blocking monoclonal antibody. Refer to current IB for product details

Experimental: Urothelial cancer Drug: Nintedanib
Nintedanib oral tablets. An angiokinase inhibitor targeting VEGFR 1-3, FGFR 1-3, and PDGFR α/β as well as RET. Refer to current IB for product details

Drug: Pembrolizumab
Pembrolizumab, Intravenous. An IgG4 anti-PD-1 blocking monoclonal antibody. Refer to current IB for product details

Experimental: Renal Cell cancer (RCC) Drug: Nintedanib
Nintedanib oral tablets. An angiokinase inhibitor targeting VEGFR 1-3, FGFR 1-3, and PDGFR α/β as well as RET. Refer to current IB for product details

Drug: Pembrolizumab
Pembrolizumab, Intravenous. An IgG4 anti-PD-1 blocking monoclonal antibody. Refer to current IB for product details

Experimental: Colo Rectal Cancer Drug: Nintedanib
Nintedanib oral tablets. An angiokinase inhibitor targeting VEGFR 1-3, FGFR 1-3, and PDGFR α/β as well as RET. Refer to current IB for product details

Drug: Pembrolizumab
Pembrolizumab, Intravenous. An IgG4 anti-PD-1 blocking monoclonal antibody. Refer to current IB for product details

Experimental: Ovarian cancer (OC) Drug: Nintedanib
Nintedanib oral tablets. An angiokinase inhibitor targeting VEGFR 1-3, FGFR 1-3, and PDGFR α/β as well as RET. Refer to current IB for product details

Drug: Pembrolizumab
Pembrolizumab, Intravenous. An IgG4 anti-PD-1 blocking monoclonal antibody. Refer to current IB for product details

Experimental: Hepatocellular (HCC) Drug: Nintedanib
Nintedanib oral tablets. An angiokinase inhibitor targeting VEGFR 1-3, FGFR 1-3, and PDGFR α/β as well as RET. Refer to current IB for product details

Drug: Pembrolizumab
Pembrolizumab, Intravenous. An IgG4 anti-PD-1 blocking monoclonal antibody. Refer to current IB for product details

Experimental: Mesothelioma (MPM) Drug: Nintedanib
Nintedanib oral tablets. An angiokinase inhibitor targeting VEGFR 1-3, FGFR 1-3, and PDGFR α/β as well as RET. Refer to current IB for product details

Drug: Pembrolizumab
Pembrolizumab, Intravenous. An IgG4 anti-PD-1 blocking monoclonal antibody. Refer to current IB for product details




Primary Outcome Measures :
  1. MTD of Nintedanib [ Time Frame: Assessed within 24 months after study start ]
    The primary endpoint is to determine the MTD of nintedanib based on the assessment of DLT occurrence during treatment Course 1.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age ≥ 18
  2. Cytologically or histologically confirmed diagnosis of advanced solid tumor for the initial cohort (all tumor types).

    And for the Expansion cohorts:

    2.1. Patients with locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumor histology in the first line of systemic therapy. Relapsing stage III previously irradiated are allowed if the irradiation has been performed more than 6 months before C1D1.

    2.2 Patients with locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) of squamous cell tumor histology in the first line of systemic therapy. Relapsing stage III previously irradiated are allowed if the irradiation has been performed more than 6 months before C1D1.

    2.3. Patients with advanced Urothelial cancer

    2.4. Patients with advanced Renal Cell cancer (RCC)

    2.5. Patients with advanced Mesothelioma (MPM)

    2.6. Patients with advanced squamous cell carcinoma in cervical cancer

    2.7. Patients with advanced Hepatocellular (HCC)

    2.8. Patients with advanced thymic carcinoma

  3. ECOG performance status of score 0 or 1
  4. Adequate organ function as defined by the following criteria:

    • Proteinuria ≤ Grade 2 NCI CTCAE v4.03
    • Serum creatinine ≤1.5 x ULN or calculated creatinine clearance ≥ 40 mL/min
    • Total bilirubin within normal range ≤1.5 x ULN (≤ 3 if HCC)
    • AST and ALT ≤1.5 x upper limit of normal (ULN); if liver metastases AST and ALT ≤2.5 x ULN if HCC
    • Coagulation parameter : International normalized ratio (INR) < 2, prothrombin time (PT) and partial thromboplastin time (PTT) < 50% of deviation of ULN
    • Absolute Neutrophils count (ANC) ≥1 000 cells/mm3
    • Platelets ≥100 000 cells/mm3
    • Hemoglobin ≥ 9.0 g/dL
  5. Failure of at least one prior line of chemotherapy (except for the NSCLC cohorts)
  6. At least one measurable lesion according to RECIST v1.1 criteria and modified RECIST for mesothelioma only or any other baseline prerequisite for the assessment of the principal judgment criteria.
  7. Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test within 7 days prior to initiation of treatment. Both sexually active females and males (and their female partners) patients must agree to use two methods of effective contraception, one of them being a barrier method, or to abstain from sexual activity during the study and for at least 4 months after last study drug administration.
  8. Signed and dated written informed consent prior to admission to the study
  9. Patient affiliated to a social security regimen or beneficiary or the same

Exclusion Criteria:

  1. Prior treatment with nintedanib
  2. Known hypersensitivity to trial drugs or their excipients, peanut or soya or to contrast media
  3. Prior treatment with pembrolizumab or any other anti PD1 or anti-PDL1 agents
  4. Concurrent steroid medication (except topical or aerosol steroids). Any steroid medication should have been stopped for more than 7 days prior beginning of therapy.
  5. History of autoimmune/immune mediated inflammatory disease, including but not limited to colitis, pneumonitis, hepatitis, hypophysitis, nephritis, hyperthyroidism, systemic lupus erythematous, rheumatoid arthritis, inflammatory bowel disease, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, vasculitis, or glomerulonephritis. Patients with a history of auto-immune endocrinopathy (hypo/hyper thyroiditis,type 1 diabetes mellitus, …) and who are stable on hormone replacement therapy are eligible for the study. Patients with a history of vitiligo, pelade, cutaneous psoriasis and grade 1-2 Sjogren syndrome are eligible.
  6. Chemo-, hormono-, radio- (except for brain and extremities) or immunotherapy or therapy with monoclonal antibodies or small tyrosine kinase inhibitors within the past 4 weeks or 5 half-life times (whatever the shortest) prior to treatment with the trial drugs.
  7. Administration of a live, attenuated vaccine within 4 weeks before registration
  8. Treatment with systemic immunosuppressive medications (including but not limited to steroids azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 2 weeks prior to registration
  9. Radiotherapy to the target lesion (unless a progression after radiotherapy has been documented)
  10. Persistence of clinically relevant treatment-related toxicity from previous chemotherapy, targeted therapy and/or radiotherapy
  11. Active brain metastases or leptomeningeal disease. Clinically asymptomatic brain metastases and clinically asymptomatic leptomeningeal disease are allowed (treatment with steroids prior initiation of the trial is not allowed). Patients with Diffuse Intrinsic Pontine Gliomas, even asymptomatic, are not allowed.
  12. Radiographic evidence of cavitary or necrotic tumors or tumors with local invasion of major blood vessels
  13. History of clinically significant hemoptysis within the past 3 months (more than one teaspoon of fresh blood per day)
  14. Treatment with other investigational drugs or treatment in another clinical trial within the past 4 weeks before start of therapy or concomitantly with the trial
  15. Therapeutic anticoagulation with drugs requiring INR monitoring (except low-dose heparin and/or heparin flush as needed for maintenance of an in-dwelling intravenous devise) or anti-platelet therapy (except for low-dose therapy with acetylsalicylic acid < 325mg per day)
  16. Major injuries and/or surgery within the past 4 weeks prior to start of study treatment with incomplete wound healing and/or planned surgery during the on-treatment study period
  17. History of clinically significant hemorrhagic or thromboembolic event in the past 6 months
  18. Known inherited (genetic) predisposition to bleeding or thrombosis (such deficit in protein C/S) or acquired predisposition to thrombosis (such as anti-phospholipid syndromes)
  19. History of significant cardiovascular diseases ( i.e. uncontrolled hypertension, unstable angina, history of infarction within the past 12 months prior to start of study treatment, congestive heart failure > NYHA II, serious cardiac arrhythmia, pericardial effusion)
  20. Ongoing uncontrolled auto-immune thyroiditis. Ancient thyroiditis currently stable with substitutive therapy should not be excluded from the trial.
  21. Other malignancies within the past 5 years other than basal cell skin cancer or carcinoma in situ of the cervix. A history of more than 3 years of local prostate cancer treated by surgery and without PSA elevation since surgery, or local breast carcinoma treated by surgery without relapse are eligible.
  22. Active serious infections in particular if requiring systemic antibiotic or antimicrobial therapy

24. Known to be human immunodeficiency virus (HIV) positive; 25. Gastrointestinal disorders or abnormalities that would interfere with absorption of the study drug 26. Serious illness or concomitant non-oncological disease such as neurologic, psychiatric, infectious disease or active ulcers (gastro-intestinal tract, skin) or laboratory abnormality that may increase the risk associated with study participation or study drug administration and in the judgment of the investigator would make the patient inappropriate for entry into the study.

27. Pregnancy or breast feeding, 28. Psychological, familial, sociological or geographical factors potentially hampering compliance with the study protocol and follow-up schedule 29. Active alcohol or drug abuse


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02856425


Locations
Layout table for location information
France
Gustave Roussy
Villejuif, Val De Marne, France, 94805
Sponsors and Collaborators
Gustave Roussy, Cancer Campus, Grand Paris

Layout table for additonal information
Responsible Party: Gustave Roussy, Cancer Campus, Grand Paris
ClinicalTrials.gov Identifier: NCT02856425     History of Changes
Other Study ID Numbers: 2015-004511-21
2015/2329 ( Other Identifier: CSET Number )
First Posted: August 4, 2016    Key Record Dates
Last Update Posted: January 3, 2019
Last Verified: January 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Pembrolizumab
Nintedanib
Antineoplastic Agents, Immunological
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action